摘要
目的探讨利拉鲁肽联合二甲双胍治疗肥胖初诊2型糖尿病的临床疗效。方法选取张家口市中医院2021年6月至2022年6月收治的初诊2型糖尿病的肥胖(体质量指数≥28 kg/m2)患者102例,按给药方案的不同分为对照组(48例)和观察组(54例)。两组患者均配合适宜的有氧运动和阻力运动治疗,并予盐酸二甲双胍片口服,观察组患者加用利拉鲁肽注射液皮下注射。两组均持续治疗16周。结果观察组总有效率为92.59%,显著高于对照组的77.08%(P<0.05)。观察组患者治疗后的血管性血友病因子、内皮素-1、缺氧诱导因子1α、血管内皮生长因子水平均显著低于对照组,内脏脂肪面积及内脏脂肪量均显著少于对照组,空腹血糖、糖化血红蛋白水平及体质量指数、腰臀比均显著低于对照组(P<0.05)。观察组与对照组不良反应发生率相当(37.04%比31.25%,P>0.05)。结论利拉鲁肽联合二甲双胍能有效降低初诊2型糖尿病肥胖患者的血糖和内脏脂肪水平,对血管内皮功能有积极改善作用。
Objective To investigate the clinical efficacy of liraglutide combined with metformin in the treatment of obese patients with newly diagnosed diabetes mellitus type 2(T2DM).Methods A total of 102 obese patients(body mass index≥28 kg/m2)with newly diagnosed T2DM admitted to the Zhangjiakou Hospital of Traditional Chinese Medicine from June 2021 to June 2022 were selected and divided into the control group(48 cases)and the observation group(54 cases)according to different administration schemes.Both groups were given appropriate aerobic exercise,resistance exercise therapy and Metformin Hydrochloride Tablets(orally),on this basis,the patients in the observation group were given subcutaneous injection of Liraglutide Injection.Both groups were treated continuously for 16 weeks.Results The total effective rate in the observation group was 92.59%,which was significantly higher than 77.08%in the control group(P<0.05).After treatment,the von Willebrand factor(vWF),endothelin-1(ET-1),hypoxia-inducible factor-1α(HIF-1α),vascular endothelial growth factor(VEGF)levels in the observation group were significantly lower than those in the control group;the visceral fat area(VFA)and visceral fat mass were significantly lower than those in the control group;the fasting blood glucose(FBG)and glycosylated hemoglobin(HbA1C)levels,the body mass index and waist-hip ratio(WHR)were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(37.04%vs.31.25%,P>0.05).Conclusion Liraglutide combined with metformin can effectively reduce the blood glucose and visceral fat levels in obese patients with newly diagnosed T2DM,and has a positive effect on improving vascular endothelial function.
作者
马平平
郑文静
高慧峰
刘风
马君
MA Pingping;ZHENG Wenjing;GAO Huifeng;LIU Feng;MA Jun(Zhangjiakou Hospital of Traditional Chinese Medicine,Zhangjiakou,Hebei,China 075000;The First Hospital of Zhangjiakou,Zhangjiakou,Hebei,China 075000)
出处
《中国药业》
CAS
2023年第20期127-129,共3页
China Pharmaceuticals
基金
河北省医学科学研究课题[20211120]。
关键词
利拉鲁肽
二甲双胍
肥胖
初诊
2型糖尿病
内脏脂肪
血管内皮功能
临床疗效
liraglutide
metformin
obesity
newly diagnosis
diabetes mellitus type 2
visceral fat
vascular endothelial function
clinical efficacy
